Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma

Ahmed Mohyeldin, Huasheng Lu, Clifton Dalgard, Stephen Y. Lai, Noam Cohen, Geza Acs, Ajay Verma*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

102 Scopus citations

Abstract

Erythropoietin (Epo) is used for managing anemia in cancer patients. However, recent studies have raised concerns for this practice. We investigated the expression and function of Epo and the erythropoietin receptor (EpoR) in tumor biopsies and cell lines from human head and neck cancer. Epo responsiveness of the cell lines was assessed by Epoetin-α-induced tyrosine phosphorylation of the Janus kinase 2 (JAK2) protein kinase. Transmigration assays across Matrigel-coated filters were used to examine the effects of Epoetin-α on cell invasiveness. In 32 biopsies, we observed a significant association between disease progression and expression of Epo and its receptor, EpoR. Expression was highest in malignant cells, particularly within hypoxic and infiltrating tumor regions. Although both Epo and EpoR were expressed in human head and neck carcinoma cell lines, only EpoR was upregulated by hypoxia. Epoetin-α treatment induced prominent JAK2 phosphorylation and enhanced cell invasion. Inhibition of JAK2 phosphorylation reduced both basal and Epo-induced invasiveness. Our findings support a role for autocrine or paracrine Epo signaling in the malignant progression and local invasiveness of head and neck cancer. This mechanism may also be activated by recombinant Epo therapy and could potentially produce detrimental effects in rhEpo-treated cancer patients.

Original languageEnglish
Pages (from-to)537-543
Number of pages7
JournalNeoplasia
Volume7
Issue number5
DOIs
StatePublished - May 2005
Externally publishedYes

Keywords

  • Cancer
  • Erythropoietin
  • HIF
  • Hypoxia
  • Invasion

Fingerprint

Dive into the research topics of 'Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this